Bristol Myers Squibb (NYSE:BMY) EVP Sells $1,850,100.00 in Stock

Bristol Myers Squibb Company (NYSE:BMY) EVP David Elkins sold 30,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Bristol Myers Squibb Trading Down 3.5%

Bristol Myers Squibb stock traded down $2.16 during trading hours on Thursday, reaching $59.57. The company had a trading volume of 13,517,905 shares, compared to its average volume of 13,503,015. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a 50-day moving average price of $59.18 and a 200 day moving average price of $52.52. The firm has a market cap of $121.63 billion, a price-to-earnings ratio of 17.27, a P/E/G ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same period last year, the company posted $1.67 EPS. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. HSBC increased their target price on shares of Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Barclays started coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price target on the stock. Guggenheim reiterated a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $52.00 to $61.00 in a research report on Monday, December 15th. Finally, UBS Group reissued a “buy” rating and set a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday, March 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and an average target price of $61.41.

Key Headlines Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase‑3 data from the SCOUT‑HCM trial for Camzyos — the results (including adolescents) raise the drug’s commercial and label‑expansion potential, which could add meaningful future product revenue if regulators and payers align. BMY Announces Positive Data from the Phase 3 SCOUT‑HCM Trial of Camzyos
• Positive Sentiment: Surge in call‑option activity (≈66,895 calls, +81% vs. avg) — elevated bullish options flow suggests some traders are positioning for upside from catalysts (trial/regulatory updates or broader biotech lift).
• Neutral Sentiment: Janux Therapeutics nominated a development candidate under its BMS collaboration, which triggered a $35M milestone payment to Janux — indicates active external R&D partnering but represents routine collaboration mechanics. Janux Announces Development Candidate; $35M Milestone
• Neutral Sentiment: Market opportunity writeups (HNSCC and RCC market reports) highlight large addressable markets where BMY competes — useful long‑term context but not an immediate stock mover. HNSCC Market Projected Growth
• Neutral Sentiment: Analyst/features pieces raising attention to BMY’s earnings history and investor interest — suggests increased eyes on upcoming catalysts (earnings, regulatory updates).
• Negative Sentiment: Insider sale: EVP David V. Elkins sold 30,000 shares at ~$61.67 (≈$1.85M) and trimmed his holdings ~15.8% — a large, disclosed insider sell can weigh on sentiment even if sales are for diversification. SEC Form 4 — David V. Elkins Sale
• Negative Sentiment: Recent quarterly results (Feb 5) included an EPS miss vs. estimates and conservative FY‑2026 EPS guidance (6.05–6.35), which remains a backdrop for investor skepticism until BMY shows consistent upside to consensus.

Hedge Funds Weigh In On Bristol Myers Squibb

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in Bristol Myers Squibb by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock worth $10,719,376,000 after buying an additional 2,743,759 shares during the period. State Street Corp grew its holdings in shares of Bristol Myers Squibb by 1.4% during the 4th quarter. State Street Corp now owns 97,980,438 shares of the biopharmaceutical company’s stock worth $5,285,065,000 after acquiring an additional 1,385,206 shares during the period. Geode Capital Management LLC grew its holdings in shares of Bristol Myers Squibb by 13.1% during the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares during the period. Norges Bank bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth approximately $1,947,272,000. Finally, Ameriprise Financial Inc. lifted its stake in shares of Bristol Myers Squibb by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock valued at $1,508,099,000 after purchasing an additional 432,158 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.